Kuros Biosciences‘ MagnetOs Bone Graft Successfully Achieves Three Key Milestones

Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with MagnetOs worldwide Kuros Biosciences (“Kuros” or the […]

Weiterlesen

Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial

Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs    Data will support product approvals at hospitals […]

Weiterlesen

Kuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications

Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other […]

Weiterlesen

Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures

. Phase II data published in peer-reviewed Journal of Bone and Joint Surgery  Healing rate at six months post-surgery was higher than standard of care Significantly de-risks development of Fibrin-PTH […]

Weiterlesen

Kuros Biosciences reports continued increase in MagnetOs U.S. sales

  MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader […]

Weiterlesen